1. Home
  2. NLOP vs EDIT Comparison

NLOP vs EDIT Comparison

Compare NLOP & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NLOP

Net Lease Office Properties of Beneficial Interest

N/A

Current Price

$13.91

Market Cap

198.4M

Sector

N/A

ML Signal

N/A

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

N/A

Current Price

$2.39

Market Cap

206.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NLOP
EDIT
Founded
N/A
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.4M
206.0M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
NLOP
EDIT
Price
$13.91
$2.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$46.00
$4.50
AVG Volume (30 Days)
316.9K
1.4M
Earning Date
01-01-0001
06-08-2026
Dividend Yield
46.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$118,915,000.00
$31,937,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.64
52 Week Low
$12.76
$0.91
52 Week High
$34.53
$4.54

Technical Indicators

Market Signals
Indicator
NLOP
EDIT
Relative Strength Index (RSI) 31.73 61.36
Support Level $12.76 $2.01
Resistance Level $20.22 $2.76
Average True Range (ATR) 0.52 0.18
MACD 0.17 0.04
Stochastic Oscillator 68.74 90.78

Price Performance

Historical Comparison
NLOP
EDIT

About NLOP Net Lease Office Properties of Beneficial Interest

Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: